New scan may personalize breast cancer therapy
NCT ID NCT07586215
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether a special PET scan (HER2-PET) can predict how well the drug T-DXd works in people with advanced breast cancer. About 100 participants with HER2-positive or HER2-low breast cancer will get the scan before treatment. The goal is to see if the scan can help doctors choose the right treatment for each person.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER, METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan Cancer Hospital
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- PET scan could reveal which breast cancer patients will respond to targeted therapy
- New study aims to catch lymphedema early in breast cancer patients
- AI tool aims to predict breast cancer drug success, sparing patients unnecessary side effects
- Mapping the hidden toll: how breast cancer brain metastases affect daily life
- New decision tool aims to ease tough talks for advanced breast cancer patients